Faricimab

Faricimab
Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	VEGF-A, angiopoietin 2
Clinical data
Trade names	Vabysmo
Other names	RO6867461; RG7716; faricimab-svoa
License data	US DailyMed: Faricimab;
Pregnancy; category	AU: D;
Routes of; administration	Intravitreal
ATC code	S01LA09 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / Schedule D; US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	1607793-29-2;
DrugBank	DB15303;
UNII	QC4F7FKK7I;
KEGG	D11516;
Chemical and physical data
Formula	C6506H9968N1724O1026S45
Molar mass	130197.05 g·mol−1

Faricimab, sold under the brand name Vabysmo (/vəˈbaɪzmoʊ/ və-BYEZ-mow), is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Faricimab is the first bispecific monoclonal antibody to target both vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2). By targeting these pathways, faricimab stabilizes blood vessels in the retina. It is given by intravitreal injection (injection into the eye) by an ophthalmologist.

Faricimab was developed by Roche in Penzberg (Roche Innovation Center Munich). Faricimab was approved for medical use in the United States in January 2022, and in the European Union in September 2022.